Summary
A licence term sheet is the short document that precedes the long one. It is typically two to five pages, it is usually described as non-binding, and it sets the commercial architecture that the definitive agreement will then spend thirty pages implementing. Very little of substance is renegotiated after it is signed.
That is the reason to read it slowly. By the time a licensee's counsel produces the full agreement, the royalty rate, the royalty base, the field of use and the termination mechanics have all been agreed in principle, and reopening them looks like bad faith rather than diligence. What follows is an anatomy of the clauses that decide the money, in the order they usually appear.
Status
What Is Binding in a Document That Says It Is Not
Almost every term sheet carries a line declaring that it creates no legally enforceable obligation. That line is normally accurate about the commercial terms and inaccurate about three others. Confidentiality provisions bind on signature. An exclusivity or no-shop clause — an undertaking not to approach other prospective licensees for a stated period — binds on signature. So does any clause on governing law or dispute forum, along with any allocation of costs.
The exclusivity period is the one that costs inventors money. Sixty to ninety days of negotiating exclusivity is ordinary and defensible. Six months is not, particularly where the document imposes no reciprocal obligation on the licensee to do anything at all during that time. An inventor who signs a nine-month no-shop has handed over the only leverage they possess, which is the credible possibility of a competing offer, and receives nothing in exchange but the other side's continued attention.
Read the survival clause too. If the term sheet expires, does the confidentiality obligation continue, and for how long? Three to five years is standard for commercial information. A confidentiality term that lapses in twelve months while the negotiation itself takes ten is decorative.
The Base
The Royalty Rate Matters Less Than What It Multiplies
Inventors negotiate hard on the percentage and casually on the definition it applies to, which is the wrong way round. A five per cent royalty on a base that has been narrowed by unlimited deductions can pay less than three per cent on gross invoiced price.
Rates cluster by category rather than by merit. Consumer hardware where the invention is the product commonly runs between three and six per cent of net sales. Where the invention is one component inside a larger assembly, one to two per cent is more usual, sometimes applied to the value of the component rather than the finished item. A frequently used cross-check is the twenty-five per cent convention: the licensor's share is set at roughly a quarter of the operating profit the licensee expects the product to generate, which for a product carrying a twenty per cent margin lands at about five per cent of sales. It is a rule of thumb, not a valuation, but it is a useful way of testing whether a proposed figure is inside the normal range.
The definition of net sales is where the negotiation actually is. Deductions for returns, trade discounts, freight, insurance and sales taxes are conventional. Deductions for marketing allowances, promotional rebates, distributor co-op payments and unspecified "customary industry adjustments" are not, and they are how a base erodes. The workable answer is a hard cap: aggregate deductions of no more than eight to ten per cent of gross invoiced price, with anything beyond that borne by the licensee.
Two clauses set the payment. One is a number the inventor argues about for a week; the other is a definition they read once. The definition is worth more.
On where royalty negotiations are actually decided
Also establish who is captured. Royalties should accrue on sales by the licensee, its affiliates and its sublicensees, and on transfers to related parties at an arm's-length equivalent price. Without that, a product can be sold to a wholly owned subsidiary at cost and the royalty computed on the cost.
Diligence
Advances, Minimums and the Obligation to Actually Sell
An exclusive licence removes the inventor's right to license anyone else. If the licensee then does nothing, the invention is frozen for the life of the agreement, and the inventor's remedy is whatever the document provides. Three mechanisms provide it.
The first is the advance, a payment on signature that is usually creditable against future royalties. Figures between five and twenty-five thousand in the relevant currency are common for consumer products, and the number matters less than the fact of it: a licensee that has paid nothing has risked nothing. The second is minimum annual royalties — a floor payable whether or not any units move, typically nil in the first year while tooling is built, then rising in steps from year two. The third is a milestone schedule: a working production sample by a stated month, regulatory clearance where applicable, and first commercial sale within eighteen to twenty-four months of signature.
Each mechanism needs a consequence attached. The usual and correct one is that failure converts the licence from exclusive to non-exclusive, or terminates it outright with all rights reverting to the inventor. A minimum with no reversion attached is a request rather than an obligation.
Scope
Field of Use, Territory and the Improvements Trap
Three scope clauses decide how much of the invention is being given away, and all three are routinely drafted wider than the licensee needs.
Field of use should describe the application the licensee actually intends to sell into. A licensee planning a domestic kitchen product does not require rights across industrial, medical and institutional applications, and a licence granting all four removes markets the inventor could otherwise license separately. Similarly, territorial scope should follow the licensee's distribution reality: exclusivity across every territory in which the patent family exists, granted to a party that sells in three of them, is not a licence but an option to prevent anyone else from selling.
The improvements clause is the one most often signed without comment. A grant-back requiring the inventor to assign all future improvements to the licensee, for the duration and beyond, effectively transfers the inventor's next several years of work. The negotiated position is narrower on every axis: the grant-back covers only improvements that cannot be practised without infringing the licensed claims, it is non-exclusive, it is limited to the same field of use, and it expires with the agreement. Improvements the licensee develops should be dealt with symmetrically.
Watch the definition of licensed patents as well. It should extend to continuations, divisionals and foreign counterparts of the identified applications, and no further. A definition sweeping in "all patents owned or hereafter acquired by the licensor relating to the field" captures inventions that do not exist yet.
Exit
Term, Termination and the Right to Check the Numbers
The term should run to expiry of the last-to-expire licensed claim, with royalties stepping down if the core claim lapses earlier. Against that, look for termination for convenience: a right allowing the licensee to walk on thirty or ninety days' notice. Where it exists without a corresponding payment, the agreement is an option dressed as a licence, and the inventor is carrying all the risk of the development period.
Two administrative clauses are worth as much as the royalty rate. The first is audit: the right to appoint an accountant to inspect the sales records once a year, with the licensee bearing the cost of the audit where an underpayment above five per cent is found. Royalty reporting is self-assessed, and self-assessment without inspection rights is optimistic. The second is prosecution cost. Maintenance and renewal fees fall due at intervals over the life of the patent and rise as it ages; the document should say plainly who pays them, and if the licensee does, whether those payments are creditable against royalties. It should also say what happens if the licensee decides a filing in a given territory is no longer worth maintaining — the answer should be that the inventor is offered the chance to take it over.
Reversion is the clause that makes every other clause enforceable. Without a defined route back, an unperformed licence simply sits there for a decade.
On why termination is read before signature, not after
Finally, note what the term sheet reveals about the counterparty. A licensee that has costed tooling, named a launch window and proposed realistic minimums has done work. Documented cases where an independent invention reached retail — the account of how one household device moved from concept into production, and the fuller record of the inventors behind it — consistently show a commercial partner with specific plans rather than general enthusiasm. Press coverage of invention prefers the moment of insight, and the wider cultural appetite for innovation stories rarely lingers on royalty definitions, but a practical walk-through of turning an idea into a product puts the negotiation where it belongs: at the end of a paper trail. A licence term sheet is the last of the five documents set out in this account of the paperwork every inventor ends up needing, and the only one drafted by somebody whose interests differ from yours.
Read it once for the numbers, once for the definitions, and once for the words "sole", "all" and "perpetual". Then send it to a lawyer.
End of paper